CD274 and lung carcinoma: We sought to explore demographic and clinical risk factors for irAEs in patients receiving anti-PD1 or anti-PDL1 in a large multiethnic cohort of patients with lung cancer treated with ICIs, allowing for particularly robust comparisons of ICIs alone versus concurrent chemotherapy, as well as racial subgroups.